AIM ImmunoTech Inc. [AMEX: AIM] jumped around 0.08 points on Thursday, while shares priced at $2.08 at the close of the session, up 4.00%. The company report on July 9, 2021 that AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy.
Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen’s effectiveness against those, and potentially other viruses.
AIM ImmunoTech Inc. (NYSE American: AIM) announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.
AIM ImmunoTech Inc. stock is now 16.20% up from its year-to-date (YTD) trading value. AIM Stock saw the intraday high of $2.19 and lowest of $2.01 per share. The company’s 52-week high price is 3.16, which means current price is +18.17% above from all time high which was touched on 02/10/21.
Compared to the average trading volume of 514.96K shares, AIM reached a trading volume of 2899406 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about AIM ImmunoTech Inc. [AIM]?
The Average True Range (ATR) for AIM ImmunoTech Inc. is set at 0.08, with the Price to Sales ratio for AIM stock in the period of the last 12 months amounting to 1010.05. The Price to Book ratio for the last quarter was 1.35, with the Price to Cash per share for the same quarter was set at 1.03.
How has AIM stock performed recently?
AIM ImmunoTech Inc. [AIM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.96. With this latest performance, AIM shares dropped by -3.70% in over the last four-week period, additionally plugging by 4.52% over the last 6 months – not to mention a drop of -29.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIM stock in for the last two-week period is set at 52.53, with the RSI for the last a single of trading hit 57.22, and the three-weeks RSI is set at 50.51 for AIM ImmunoTech Inc. [AIM]. The present Moving Average for the last 50 days of trading for this stock 2.10, while it was recorded at 2.01 for the last single week of trading, and 2.12 for the last 200 days.
AIM ImmunoTech Inc. [AIM]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AIM ImmunoTech Inc. [AIM] shares currently have an operating margin of -9087.73 and a Gross Margin at -394.48. AIM ImmunoTech Inc.’s Net Margin is presently recorded at -8834.36.
Return on Total Capital for AIM is now -35.75, given the latest momentum, and Return on Invested Capital for the company is -34.98. Return on Equity for this stock declined to -38.81, with Return on Assets sitting at -16.49. When it comes to the capital structure of this company, AIM ImmunoTech Inc. [AIM] has a Total Debt to Total Equity ratio set at 3.73. Additionally, AIM Total Debt to Total Capital is recorded at 3.59, with Total Debt to Total Assets ending up at 2.06. Long-Term Debt to Equity for the company is recorded at 3.32, with the Long-Term Debt to Total Capital now at 3.16.
Reflecting on the efficiency of the workforce at the company, AIM ImmunoTech Inc. [AIM] managed to generate an average of -$626,087 per employee. Receivables Turnover for the company is 0.17 with a Total Asset Turnover recorded at a value of 0.00.AIM ImmunoTech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 52.80 and a Current Ratio set at 52.80.
Earnings analysis for AIM ImmunoTech Inc. [AIM]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AIM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AIM ImmunoTech Inc. go to 25.00%.
Insider trade positions for AIM ImmunoTech Inc. [AIM]
There are presently around $15 million, or 15.40% of AIM stock, in the hands of institutional investors. The top three institutional holders of AIM stocks are: MORGAN STANLEY with ownership of 2,505,954, which is approximately 150.893% of the company’s market cap and around 0.70% of the total institutional ownership; VANGUARD GROUP INC, holding 1,926,399 shares of the stock with an approximate value of $4.01 million in AIM stocks shares; and BLACKROCK INC., currently with $2.04 million in AIM stock with ownership of nearly 91.67% of the company’s market capitalization.
Positions in AIM ImmunoTech Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 22 institutional holders increased their position in AIM ImmunoTech Inc. [AMEX:AIM] by around 4,475,044 shares. Additionally, 10 investors decreased positions by around 150,732 shares, while 9 investors held positions by with 2,807,277 shares. The mentioned changes placed institutional holdings at 7,433,053 shares, according to the latest SEC report filing. AIM stock had 9 new institutional investments in for a total of 725,363 shares, while 3 institutional investors sold positions of 24,464 shares during the same period.